Risk of COVID-19 and its complications in patients with atopic dermatitis undergoing dupilumab treatment—a population-based cohort study

The risk of coronavirus disease (COVID-19) infection and its complications among patients with atopic dermatitis (AD) treated by dupilumab is yet to be determined. We aimed to assess the risk of SARS-CoV-2 infection, COVID-19-associated hospitalization, and mortality among patients with AD treated b...

Descripción completa

Detalles Bibliográficos
Autores principales: Kridin, Khalaf, Schonmann, Yochai, Solomon, Arie, Onn, Erez, Bitan, Dana Tzur, Weinstein, Orly, Cohen, Arnon D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8514206/
https://www.ncbi.nlm.nih.gov/pubmed/34647194
http://dx.doi.org/10.1007/s12026-021-09234-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8514206/
https://www.ncbi.nlm.nih.gov/pubmed/34647194
http://dx.doi.org/10.1007/s12026-021-09234-z

Ejemplares similares